Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 295-297, 2005; 10.1373/clinchem.2004.044826
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Charlton-Menys, V.
Right arrow Articles by Durrington, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Charlton-Menys, V.
Right arrow Articles by Durrington, P. N.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
(Clinical Chemistry. 2005;51:295-297.)
© 2005 American Association for Clinical Chemistry, Inc.


Editorials

Apolipoprotein A5 and Hypertriglyceridemia

Valentine Charlton-Menys and Paul N. Durringtona

1 Division of Cardiovascular Medicine, Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, United Kingdom

aAuthor for correspondence.

The first 20% of the full text of this article appears below.

Hypertriglyceridemia is associated with increased risk of coronary heart disease (CHD) (1)(2)(3)(4)(5), and it is an integral component of the overlapping syndromes of familial combined hyperlipidemia, insulin resistance syndrome, atherogenic lipoprotein profile, and hyperapobetalipoproteinemia (6). More than one mechanism may be involved in the increased risk of CHD associated with increased serum triglycerides:

The most common reason for an increase in circulating triglycerides is increased hepatic secretion of VLDL (11)(12)(. . . [Full Text of this Article]




eLetters:

Read all eLetters

Apo A5 S19W in ApoE 2/2 causes hypertriglyceridemia
Juergen R. Schaefer
Clinical Chemistry Online, 14 Mar 2005 [Full text]
eLetter reply to Juergen R. Schaefer's eLetter
Paul N. Durrington
Clinical Chemistry Online, 28 Mar 2005 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.